A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD

NCT03345082 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

366

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL: OPT-302
BIOLOGICAL: ranibizumab
OTHER: sham intravitreal injection

Sponsor

Opthea Limited